

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

NCT00246857

Status	RECRUITING
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	5,000 participants

Key Eligibility Criteria

Inclusion (2)

- Patients known to have or suspected of having an inherited immune cell homeostasis, programmed cell death susceptibility syndrome, lymphocyte developmental block, or defective immune cell effector functions will be eligible for enrollment. We will enroll
- patients with suspected disease if the investigator agrees that there is a high index of suspicion. Blood relatives of enrolled patients will be eligible for enrollment. There will be no limit as to age, sex, race, or disability.

Exclusion (1)

- Severely debilitated health status or poor venous access may preclude obtaining adequate specimens for analysis. The minimum weight for infants on this protocol is 3 kg because of the limits of maximal acceptable blood draw volumes and minimum requirement for core laboratory tests would exceed the acceptable volume.

Locations (7 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Ankara Medical University, Ankara, Turkey (Türkiye)
... and 4 more locations